[
    "arboxamide;(1R,2S,5S)\u2014N\u2014((S)-1-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)-6,6-dimethyl-3-(2-(trifluoromethyl)isonicotinoyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide;(1R,2S,5S)-3-(2-acetamido-5,5,5-trifluoro-4-methylpentanoyl)-N\u2014((S)-1-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;(1R,2S,5S)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-N\u2014((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide;N<sup>1</sup>\u2014((S)-1-(((R)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)-N<sup>2</sup>-(2-(trifluoromethyl)phenyl)oxalamide;(R)\u2014N\u2014((S)-3-(3-fluorophenyl)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-2-hydroxy-4-methylpentanamide;N<sup>1</sup>-(4-fluorobicyclo[2.2.2]octan-1-yl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)oxalamide;(S)\u2014N\u2014((S)-1-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)-4,4-dimethyl-2-(4-methylpentanamido)pentanamide;(S)-3-((S)-2-(4-methoxy-1H-indole-2-carboxamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl pentadecanoate; and(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopiperidin-3-yl)butyl 2-cyanobenzoate, or a pharmaceutically acceptable salt thereof.\n</p>In some embodiments, the compound or pharmaceutically acceptable salt thereof may demonstrate an EC50 value (e.g., in Hela cells) of less than 0.05 \u03bcM. For example, the compound may be selected from the group consisting of:\nN<sup>1</sup>-(2,6-diethylphenyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)oxalamide;N<sup>1</sup>-(2,6-diethylphenyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)oxalamide;(1R,2S,5S)\u2014N\u2014((S)-1-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;N<sup>1</sup>-(2-fluorophenyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)oxalamide;N<sup>1</sup>\u2014((S)-3-cyclopropyl-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-N<sup>2</sup>-(o-tolyl)oxalamide;N<sup>1</sup>\u2014((S)-3-cyclopropyl-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-N<sup>2</sup>-(2-fluorophenyl)oxalamide;N<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)-N<sup>2</sup>-(3-(trifluoromethoxy)phenyl)oxalamide;N<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)-N<sup>2</sup>-(2-(trifluoromethyl)phenyl)oxalamide;N<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)-N<sup>2</sup>-(2-(trifluoromethoxy)phenyl)oxalamide;N<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)-N<sup>2</sup>-(3-(trifluoromethyl)phenyl)oxalamide;N<sup>1</sup>-(2-(tert-butyl)phenyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)oxalamide;N<sup>1</sup>-(3-chlorophenyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)oxalamide;(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopiperidin-3-yl)butyl isopropyl carbonate;(S)-3-((S)-2-(1H-indole-2-carboxamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl heptanoate; and(S)-3-((S)-2-(4-methoxy-1H-indole-2-carboxamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl heptanoate, or a pharmaceutically acceptable salt thereof.\n</p>In some embodiments, the compound or pharmaceutically acceptable salt thereof may demonstrate an EC50 value (e.g., in Hela cells) of from 0.05 \u03bcM to less than 0.2 \u03bcM. For example, the compound may be selected from the group consisting of:\nN<sup>1</sup>-(2-fluorophenyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)oxalamide;(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl 1-cyclohexylpiperidine-4-carboxylate;N<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-N<sup>2</sup>-(3-methoxyphenyl)oxalamide;(S)-3-((S)-2-(2-((2,6-dimethylphenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl 2-oxo-2-phenylacetate;(S)-3-((S)-2-(2-(cyclohexylamino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl heptanoate;N<sup>1</sup>-(2-fluorophenyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)oxalamide;N<sup>1</sup>\u2014((S)-3-cyclohexyl-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-N<sup>2</sup>-(2-fluorophenyl)oxalamide;N<sup>1</sup>\u2014((S)-3-cyclohexyl-1-(((R)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-N<sup>2</sup>-(2-fluorophenyl)oxalamide;N<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-N<sup>2</sup>-(o-tolyl)oxalamide;(1S,3",
    "oxopiperidin-3-yl)butyl acetate;(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl acetate;(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl isopropyl carbonate;N<sup>1</sup>-(3-fluorobicyclo[1.1.1]pentan-1-yl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-3-(1-methylcyclobutyl)-1-oxopropan-2-yl)oxalamide;N<sup>1</sup>-(tert-butyl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-3-(1-methylcyclobutyl)-1-oxopropan-2-yl)oxalamide;N\u2014((S)-3-cyclopropyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)-5-(2-fluorophenyl)isoxazole-3-carboxamide;5-(2-fluorophenyl)-N\u2014((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)isoxazole-3-carboxamide;(1R,2S,5S)-3-(2-acetamido-5,5,5-trifluoro-4-methylpentanoyl)-N\u2014((S)-1-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;(S)-3-((S)-2-(4-methoxy-1H-indole-2-carboxamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl pentadecanoate; and(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopiperidin-3-yl)butyl 2-cyanobenzoate,\n\nor a pharmaceutically acceptable salt thereof.\n\n</p>In some embodiments, the compound or pharmaceutically acceptable salt thereof may demonstrate an EC50 value (e.g., in Hela cells) of from 0.2 \u03bcM to less than 0.5 \u03bcM. For example, the compound may be selected from the group consisting of:\nN\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-methoxy-1H-indole-2-carboxamide;(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl pentadecanoate;(S)-3-((S)-2-(2-((2-fluorophenyl)amino)-2-oxoacetamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl 4-(piperidin-1-yl)cyclohexane-1-carboxylate;N<sup>1</sup>\u2014((S)-3-cyclohexyl-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-N<sup>2</sup>-(o-tolyl)oxalamide;N<sup>1</sup>-(2,6-dimethylphenyl)-N<sup>2</sup>-((2S)-1-((4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)oxalamide;N<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-N<sup>2</sup>-(2-methoxy-6-methylphenyl)oxalamide;(S)-3-((S)-3-cyclohexyl-2-(2-(cyclohexylamino)-2-oxoacetamido)propanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl heptanoate;N<sup>1</sup>-(3-fluorobicyclo[1.1.1]pentan-1-yl)-N<sup>2</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl)oxalamide;(1R,2S,5S)-6,6-dimethyl-N\u2014((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-3-(2-(4-(trifluoromethoxy)phenoxy)acetyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide;(S)-5-(2-((2-fluorophenyl)amino)-2-oxoacetyl)-N\u2014((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)-5-azaspiro[2.4]heptane-6-carboxamide;(S)-3-((S)-2-(4-methoxy-1H-indole-2-carboxamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl 1-cyclohexylpiperidine-4-carboxylate;N\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-methoxy-1H-indole-2-carboxamide; and(1R,2S,5S)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-N\u2014((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide,\n\nor a pharmaceutically acceptable salt thereof.\n\n</p>In some embodiments, the compound or pharmaceutically acceptable salt thereof may demonstrate an EC50 value (e.g., in Hela cells) of from 0.5 \u03bcM to 1 \u03bcM. For example, the compound may be selected from the group consisting of:\nN<sup>1</sup>\u2014((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-N<sup>2</sup>-(1-(p-tolyl)cyclopropyl)oxalamide;(1S,3aR,6aS)-2-(2-(tert-butylamino)-2-oxoacetyl)-N\u2014((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide;N<sup>1</sup>-cyclohexyl-N<sup>2</sup>\u2014((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)oxalamide;(1S,3aR,6aS)-2-(2-oxo-2-((1,1,1-trifluoro-2-methylpropan-2-yl)amino)acetyl)-N\u2014((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide;(1R,2S,5S)-3-(2-(cyclohexylamino)-2-oxoacetyl)-6,6-dimethyl-N\u2014((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide;N<sup>1</sup>\u2014((S)-1-(((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)amino)-4-methyl-1-oxopentan-2-yl)-N<sup>2</sup>-(2-fluorophenyl)oxalamide;(1S,3aR,6aS)\u2014N\u2014((S)-1-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)-2-(2-((2-fluorophenyl)amino)-2-oxoacetyl)octahydrocyclopenta[c]pyrrole-1-carboxamide;(1S,3aR,6aS)\u2014N\u2014((S)-1-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)-2-(2-(2,4-dichlorophenoxy)acetyl)octahydrocyclopenta[c]pyrrole-1-carboxamide;N<sup>1</sup>\u2014((S)-3-cyclopropyl-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-N<sup>2</sup>-(4-fluorobicyclo[2.2.2]o",
    "oxo-1-((S)-2- oxopiperidin-3-yl)butan-2-yl)amino)- 1-oxopropan-2-yl)-2-hydroxy-4- methylpentanamide480.3504&gt;1 \u03bcM 135<img id=\"EMI-C00213\" path=\"US20230033285A1-20230202-C00213.TIF\" file=\"https://surechembl.org/api/assets/attachment/1024936735/US/20230202/A1/020230/03/32/85/US20230033285A1-20230202-C00213.TIF\"/>N<sup>1</sup>-(4-fluorobicyclo[2.2.2]octan-1-yl)- N<sup>2</sup>-((S)-1-(((S)-4-hydroxy-3-oxo-1- ((S)-2-oxopiperidin-3-yl)butan-2- yl)amino)-4-methyl-1-oxopentan-2- yl)oxalamide511.3798&gt;1 \u03bcM 136<img id=\"EMI-C00214\" path=\"US20230033285A1-20230202-C00214.TIF\" file=\"https://surechembl.org/api/assets/attachment/1024935803/US/20230202/A1/020230/03/32/85/US20230033285A1-20230202-C00214.TIF\"/>(S)-N-((S)-1-cyano-2-((S)-2- oxopiperidin-3-yl)ethyl)-4,4-dimethyl- 2-(4-methylpentanamido)pentanamide393.4136&gt;1 \u03bcM 137<img id=\"EMI-C00215\" path=\"US20230033285A1-20230202-C00215.TIF\" file=\"https://surechembl.org/api/assets/attachment/1024935879/US/20230202/A1/020230/03/32/85/US20230033285A1-20230202-C00215.TIF\"/>(S)-3-((S)-2-(4-methoxy-1H-indole-2- carboxamido)-4-methylpentanamido)- 2-oxo-4-((S)-2-oxopyrrolidin-3- yl)butyl pentadecanoate698.2** 138<img id=\"EMI-C00216\" path=\"US20230033285A1-20230202-C00216.TIF\" file=\"https://surechembl.org/api/assets/attachment/1024935588/US/20230202/A1/020230/03/32/85/US20230033285A1-20230202-C00216.TIF\"/>(S)-3-((S)-2-(2-((2- fluorophenyl)amino)-2- oxoacetamido)-4- methylpentanamido)-2-oxo-4-((S)-2- oxopiperidin-3-yl)butyl 2- cyanobenzoate608.53***EC50: &lt;0.05 \u03bcM: ****0.05-&lt;0.2 \u03bcM: ***0.2-&lt;0.5 \u03bcM: **0.5-1.0 \u03bcM: *</p>TABLE 2Compound<sup>1</sup>H NMR Data18<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) \u03b4 ppm 8.57-8.52 (m, 3H), 7.65 (s, 1H), 4.83(s, 2H), 4.51-4.30 (m, 2H), 3.55 (d, J = 8.6 Hz, 1H), 3.21-3.05 (m, 2H), 2.36(t, J = 7.3 Hz, 2H), 2.29- 2.26 (m, 1H), 2.16-2.08 (m, 1H), 2.05-1.95 (m, 1H),1.72-1.45 (m, 11H), 1.38-1.26 (m, 11H), 1.12-1.02 (s, 1H), 0.89-0.85 (m,9H).19<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) \u03b4 ppm 8.57-8.53 (m, 3H), 7.65 (s, 1H), 4.83(s, 2H), 4.39-4.34 (m, 2H), 3.32-3.16 (m, 1H), 3.16-3.09 (m, 2H), 2.50-2.49(m, 2H), 2.38-2.35 (m, 1H), 2.34-2.33 (m, 1H), 2.33-1.70 (m, 1H), 1.67-1.51(m, 14H), 1.29-1.24 (m, 13H), 1.13-1.09 (m, 4H), 0.90-0.84 (m, 5H).20<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) \u03b4 ppm 10.0(s, 1H), 8.90 (d, J = 8.8 Hz, 1H),8.55 (d, J = 8.0 Hz, 1H), 7.63 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.31-7.11 (m,7H), 5.09 (t, J = 6.0 Hz, 1H), 4.66-4.64 (m, 1H), 4.49 (m, 1H), 4.25-4.09 (m,2H), 3.16-3.02 (m, 4H), 2.32-2.29 (m, 1H), 2.15 (s, 4H), 1.93 (m, 1H), 1.67-1.63 (m, 2H).21(400 MHz, DMSO-d<sub>6</sub>) \u03b4 ppm 10.29 (s, 1H), 8.90 (d, J = 8.5 Hz, 1H), 8.49 (d,J = 8.0 Hz, 1H), 7.69 (td, J = 7.8, 1.9 Hz, 1H), 7.46 (s, 1H), 7.35-7.19 (m,3H), 5.09 (t, J = 5.9 Hz, 1H), 4.49 (ddd, J= 11.5, 7.9, 3.8 Hz, 1H), 4.43-4.34 (m, 1H), 4.23 (dd, J = 18.7, 6.1Hz, 1H), 4.13 (dd, J = 18.8, 5.8 Hz, 1H),3.14-3.07 (m, 2H), 3.02-2.87 (m, 1H), 2.24-2.05 (m, 2H), 1.89-1.79(m, 1H), 1.78-1.48 (m, 5H), 1.3"
]